The use of AI in the health care industry has been dealt a blow after IBM Watson Health said it was reducing its Watson for Drug Discovery product due to a "lacklustre financial performance". According to STAT News, sources said IBM will no longer market or develop the unit, which will remain accessible to existing users, and will instead focus on clinical trial matching. In an interview with Reuters, IBM's chief executive officer Ginni Rometty said: "We are not going to be able to continue doing this work as we have done over the last few years because
The use of AI in the health care industry has been dealt a blow after IBM Watson Health said it was reducing its Watson for Drug Discovery product due to a "lacklustre financial performance". According to STAT News, sources said IBM will no longer market or develop the unit, which will remain accessible to existing users, and will instead focus on clinical trial matching. IEEE Spectrum recently spotlighted the paucity of results from collaborations between medical firms and IBM Watson Health, amid continued uncertainty surrounding the clinical benefits of AI.